查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1138266

全球额颞叶疾病药物市场 - 2022-2029

Global Frontotemporal Disorders Treatment Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

全球额颞叶疾病治疗市场的增长受到痴呆症和其他额颞叶疾病患病率上升、药物开发补贴增加以及政府和非政府组织资助等因素的推动，是推动增长的主要因素.

预计在预测期内，不断进步的技术进步将推动全球额颞叶疾病治疗市场。

根据世界卫生组织 (WHO) 的数据，大约有 5000 万人患有痴呆症，每年大约有 1000 万新病例，这有望推动该行业的发展。

额颞叶痴呆占所有痴呆患者的 2-5%。预计到 2050 年，痴呆症的患病率将增加两倍。根据痴呆症统计研究所的数据，预计痴呆症患者人数将从 2018 年的 5000 万增加到 2050 年的 1.52 亿，增加 204%。预计痴呆患者人数的增加将进一步增加额颞叶痴呆病例，进一步增加对额颞叶疾病治疗药物和药物的需求。

政府增加对寻找目标疾病治疗方法的研究工作的支持和资金也有望推动市场增长。一些组织参与了新药的开发，包括美国国立卫生研究院 (NIH)、阿尔茨海默氏症协会和美国国家老龄化研究所。 2019 年，美国国立卫生研究院在阿尔茨海默病相关痴呆 (ADRD) 研究项目上花费了约 3.87 亿美元。预计这些举措将在预测期内推动市场增长。

新兴国家对目标疾病缺乏认识可能会阻碍市场增长

额颞叶痴呆作为痴呆症的治疗剂在世界范围内被广泛认可。糟糕的治疗方案和缺乏新疗法也限制了额颞叶疾病治疗市场的增长。

行业分析

全球额颞叶疾病治疗市场根据各种行业因素、未满足的需求（如波特五力分析、供应链分析、监管分析和定价分析）对市场进行了深入分析。 .

细分分析

抗抑郁药部分预计在预测期内（2022-2029 年）以最快的复合年增长率增长

根据药物类别，全球额颞叶疾病治疗市场细分为抗精神病药、认知改善剂、CNS 兴奋剂、抗抑郁药等。其中，抗抑郁药预计将在预测期内提供有利可图的机会。抗抑郁药主要用于治疗抑郁症和其他疾病，例如心境恶劣、强迫症 (OCD)、焦虑症、神经性疼痛、进食障碍和慢性疼痛。医生通常会开出其他几种抗抑郁药来有效管理患者的健康。此外，选择性5-羟色胺再摄取抑製剂（SSRIs）已被证明有益于治疗额颞叶疾病。

2018 年 10 月，灵北在印度推出 Brintellix 片剂，用于治疗重度抑郁症。此外，2019年4月，鲁邦在美国市场推出抗抑郁药氟西汀片。该片剂可用于治疗重度抑郁症和强迫症。因此，由于患者数量的增加和最近的产品发布，预计市场在预测期内将在全球范围内实现高速增长。

本报告提供了大约 40 多个市场数据表、45 多个图表和 180 页有关全球额颞叶治疗市场的信息。

内容

第1章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

  • 按治疗类别划分的市场细分
  • 按指标划分的市场细分
  • 按分销渠道划分的市场细分
  • 按地区划分的市场细分

第 4 章市场动态

  • 市场影响因素
    • 驱动程序
      • 额颞叶疾病的患病率不断上升
      • 政府和非政府组织的资助增加
    • 限制
      • 治疗费用高
    • 商机
    • 影响分析

第5章行业分析

  • 波特五力分析
  • 流行病学
  • 管道分析
  • 供应链分析
  • 定价分析
  • 监管分析
  • 未满足的需求
  • COVID-19 影响分析

第 6 章按药物类别

    • 认知功能改善剂
    • 抗精神病药
      • 阿立□唑
      • 帕潘立酮
      • 奥氮平
      • 利培酮
      • 奎硫平
      • 齐拉西酮
    • 抗抑郁药
      • 安非他酮
      • 氟伏沙明
      • 西□普兰
      • 氟西汀
      • 米曲西平
      • 帕罗西汀
      • 舍曲林
    • 中枢神经系统兴奋剂
    • 其他

第 7 章按功效和作用

    • 行为改良额颞叶痴呆 (BFTD) (BFTD)
    • 原发性进行性失语症 (PPA)
      • 语义 PPA
      • 语法 PPA
      • 徽标绘画 PPA
    • 运动功能下降
      • 皮质基底综合征 (CBS)
      • 进行性核上性麻痹 (PSP)

第 8 章分销渠道

  • 医院药房
  • 零售药房
  • 在线药店
  • 其他

第 9 章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 10 章竞争格局

  • 竞争场景
  • 市场定位/市场份额分析
  • 併购分析

第 11 章公司简介

  • Apotex Inc.
    • 公司简介
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • Johnson & Johnson
  • Auro Pharma
  • Pfizer Inc.
  • Teva Pharmaceuticals USA, Inc.
  • AstraZeneca plc.
  • Mylan N.V.
  • Sanofi S.A.
  • Valeant Pharmaceutical International
  • Eli Lilly and Company（LIST NOT EXHAUSTIVE）

第12章 DataM

简介目录
Product Code: DMMD2666

Market Overview

The Frontotemporal Disorders Treatment Market size was valued at USD 721.4 million in 2021 and is estimated to reach at a compound annual growth rate (CAGR) of 6.50% over the forecast period 2022 to 2029.

Frontotemporal disorder, commonly known as Pick disease, is a form of dementia that is caused by a family of brain disorders known as frontotemporal lobar degeneration (FTLD). Frontotemporal dementia is a rare type of dementia that causes behavior and language problems. Dementia is associated with disorders of mental abilities caused by some changes and damage in the brain and affects the front and sides of the brain.

The Frontotemporal Disorders Treatment Market study analysis offers an in-depth outlook on the market containing both quantitative, and qualitative data. It gives an outlook and forecast of the global market based on the Frontotemporal Disorders Treatment Market segmentation by drug class, procedure, and Distribution Channel. It also provides market size, and growth, along with the latest trends, opportunities, and forecast till 2029 for the global Frontotemporal Disorders Treatment Market with esteem to major countries such as the United States, Canada, Brazil, Germany, Italy, Spain, United Kingdom, Russia, European countries, United Arab Emirates, Saudi Arabia, South Africa, Japan, China, India, South Korea, Australia, and rest of the countries over the globe.

Market Dynamics

The global frontotemporal disorders treatment market growth is driven by certain factors such as the rising prevalence of dementia and other frontotemporal disorders, increasing drug development grants, and funding by the government as well as non-government organizations are the key factors driving the market growth.

The rising technological advancements, is expected to drive the global frontotemporal disorders treatment market during the forecast period;

As per the World Health Organization, about 50 Mn people have dementia, and there are around 10 Mn new cases annually, which is anticipated to boost the industry growth.

Frontotemporal dementia accounts for 2-5% of the overall dementia cases. The prevalence of dementia is projected to be triple by 2050. As per the Dementia Statistics Organization, the number of people living with dementia is projected to increase by 204% from 50 million in 2018 to 152 million by 2050. The increasing number of dementia cases will further increase the cases of frontotemporal dementia, which is expected to drive more demand for frontotemporal disorders treatment drugs and medications.

Also, the rising government support and funding for research activities to find the treatment of target disease is expected to drive the growth of the market. Several organizations are involved in developing new medications, including the National Institute of Health (NIH), Alzheimer's Association, and National Institute on Aging. In 2019, the NIH spent around US$ 387 million on research projects for Alzheimer's Disease-Related Dementias (ADRD). These initiatives are expected to boost market growth over the forecast period.

Lack of awareness towards the target disease in a developing country are likely to hinder the market growth

However, lack of proper diagnosis and higher chances of misunderstanding with Alzheimer's disease is restraining the growth of the frontotemporal dementia treatment market. Additionally poor treatment regimens lack of novel therapies is also limiting the Frontotemporal dementia treatment market growth.

Industry Analysis

The global frontotemporal disorders treatment market provides in-depth analysis of the market based on various industry factors such as porter's five force analysis, supply chain analysis, regulatory analysis, pricing analysis etc, unmet needs.

Segmentation Analysis

The antidepressants segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

Based on drug class, the global frontotemporal disorders treatment market is segmented into antipsychotics, cognitive enhancers, CNS stimulants, antidepressants, and others. Among these, antidepressants are expected to show a lucrative opportunity over the forecast period. Antidepressant drugs are mainly used for the treatment of depressive disorders and other conditions, such as dysthymia, obsessive-compulsive disorder (OCD), anxiety disorders, neuropathic pain, eating disorders, and chronic pain, among others. Several other types of antidepressants are widely prescribed by physicians to manage patient health effectively. Also, (SSRIs) selective serotonin reuptake inhibitors prove beneficial for the treatment of frontotemporal disorders.

In October 2018, Lundbeck launched Brintellix tablets, which are used for the treatment of Major Depressive Disorder in India. Furthermore, in April 2019, Lupin launched antidepressant Fluoxetine tablets in the American market. The tablets are indicated for the treatment of the major depressive disorder, and obsessive-compulsive disorder. Thus, owing to the rising patient pool and recent product launches, the market is expected to witness high growth across the globe over the forecast period.

Geographical Analysis

North America region holds the largest market share of the global frontotemporal disorders treatment market

North America region is dominating the global frontotemporal disorders treatment market accounting for the largest market share in 2019, owing to a large presence of advanced healthcare facilities and infrastructure in developed countries, such as the United States. Also, the rising prevalence of frontotemporal disorders in this region is driving the growth of the market. For instance, according to the National Institute of Neurological Disorders and Stroke, Alzheimer's disease alone, as one dementia disorder, affects over 5 million people in the United States. The toll on individuals, society, and caregivers is enormous and is expected to increase as the population ages. Frontotemporal dementia falls under rare diseases or orphan indications.

In the United States, around 30,000 to 40,000 patients are suffering from frontotemporal disorders. Treatment of frontotemporal disorders falls under the Orphan Drug Act of 1983 as orphan drug indications are those which affect less than 200,000 people in the U.S. along with similar legislation in Europe. Orphan drug designation to FTD allows the continuation of clinical trials and development of a drug with commercial incentives, prioritizing consultation by FDA on clinical studies and reduction in regulatory fees.

Competitive Landscape

The global frontotemporal disorders treatment market is competitive and consists of several major players in the market. Some of the key players which are contributing to the growth of the market include Johnson & Johnson, Apotex Inc., Auro Pharma, Pfizer Inc., Teva Pharmaceuticals USA, Inc., AstraZeneca plc., Mylan N.V., Sanofi S.A., among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the frontotemporal disorders treatment market globally. For instance, on June 15th, 2020, ACADIA Pharmaceuticals Inc. submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) to support a potential new indication for NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with dementia-related psychosis (DRP). The FDA previously granted Breakthrough Therapy Designation for pimavanserin for the treatment of hallucinations and delusions associated with DRP.

Key Companies to Watch

Pfizer Inc

Overview: Pfizer Inc. is an American multinational pharmaceutical company that offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer Limited has a portfolio of over 150 products across 15 therapeutic areas. The company develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, endocrinology, and neurology.

Product Portfolio: ZFP-TFs to down-regulate the expression of tau, a protein associated with Alzheimer's disease and frontotemporal dementia (FTD).

The global frontotemporal disorders treatment market report would provide an access to an approx. 40+ market data table, 45+ figures and 180 pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Drug Class
  • 3.2. Market snippet by Indication
  • 3.3. Market snippet by Distribution Channel
  • 3.4. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising Prevalence of Frontotemporal Disorders
      • 4.1.1.2. Increasing Funding by Government & Non-Government Organizations
      • 4.1.1.3. XX
    • 4.1.2. Restraints:
      • 4.1.2.1. High Cost of treatment
      • 4.1.2.2. XX
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Epidemiology
  • 5.3. Pipeline Analysis
  • 5.4. Supply Chain Analysis
  • 5.5. Pricing Analysis
  • 5.6. Regulatory Analysis
  • 5.7. Unmet Needs
  • 5.8. COVID-19 Impact Analysis

6. By Drug Class

  • 6.1. Introduction
  • 6.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class Segment
  • 6.3. Market Attractiveness Index, By Drug Class Segment
    • 6.3.1. Cognitive Enhancers*
      • 6.3.1.1. Introduction
      • 6.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 6.3.2. Antipsychotics
      • 6.3.2.1. Aripiprazole
      • 6.3.2.2. Paliperidone
      • 6.3.2.3. Olanzepine
      • 6.3.2.4. Risperidone
      • 6.3.2.5. Quetiapine
      • 6.3.2.6. Ziprasidone
    • 6.3.3. Antidepressants
      • 6.3.3.1. Bupropion
      • 6.3.3.2. Fluvoxamine
      • 6.3.3.3. Citalopram
      • 6.3.3.4. Fluoxetine
      • 6.3.3.5. Mitrazepine
      • 6.3.3.6. Paroxetine
      • 6.3.3.7. Sertraline
    • 6.3.4. CNS stimulants
    • 6.3.5. Others

7. By Indication

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
  • 7.3. Market Attractiveness Index, By Indication Segment
    • 7.3.1. Behaviour Variants Frontotemporal Dementia. (BFTD)*
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. Primary Progressive Aphasia (PPA)
      • 7.3.2.1. Semantic PPA
      • 7.3.2.2. Agrammatic PPA
      • 7.3.2.3. Logopenic PPA
    • 7.3.3. Motor Decline
      • 7.3.3.1. Corticobasal syndrome (CBS)
      • 7.3.3.2. Progressive supranuclear palsy (PSP)

8. By Distribution Channel

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
  • 8.3. Market Attractiveness Index, By Distribution Channel Segment
    • 8.3.1. Hospital Pharmacies*
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Online Pharmacies
    • 8.3.4. Others

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.2.6.1. The U.S.
      • 9.2.6.2. Canada
      • 9.2.6.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.3.6.1. Germany
      • 9.3.6.2. The U.K.
      • 9.3.6.3. France
      • 9.3.6.4. Italy
      • 9.3.6.5. Spain
      • 9.3.6.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.6.1. Brazil
      • 9.4.6.2. Argentina
      • 9.4.6.3. Rest of South America
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.6.1. China
      • 9.5.6.2. India
      • 9.5.6.3. Japan
      • 9.5.6.4. Australia
      • 9.5.6.5. Rest of Asia Pacific
  • 9.6. The Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Apotex Inc.*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. Johnson & Johnson
  • 11.3. Auro Pharma
  • 11.4. Pfizer Inc.
  • 11.5. Teva Pharmaceuticals USA, Inc.
  • 11.6. AstraZeneca plc.
  • 11.7. Mylan N.V.
  • 11.8. Sanofi S.A.
  • 11.9. Valeant Pharmaceutical International
  • 11.10. Eli Lilly and Company (LIST NOT EXHAUSTIVE)

12. DataM

  • 12.1. Appendix
  • 12.2. About Us and Services
  • 12.3. Contact Us